Kurzfassung

A PHASE III, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY
STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS
WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO
REMAIN SYMPTOMATIC DESPITE TREATMENT WITH
H1 ANTIHISTAMINES, H2 BLOCKERS, AND/OR
LEUKOTRIENE RECEPTOR ANTAGONISTS